NY-IWBI
5.2.2020 22:09:05 CET | Business Wire | Press release
The International WELL Building Institute (IWBI) announced today that it has passed the 500-million-square-foot mark of buildings registered and certified under the WELL Building Standard (WELL). The milestone quickly follows this month’s earlier announcement that the number of WELL Accredited Professionals (APs) and registrants has exceeded 10,000, further evidence of the accelerating growth of the global movement to help people thrive through better buildings and communities and stronger organizations.
“With more than 4,000 projects in nearly 60 countries and spanning all space types – offices, schools, hotels, residences and more – it’s clear that this second wave of sustainability has gathered powerful momentum,” said IWBI Chairman and CEO Rick Fedrizzi. “To reach a half-billion square feet of spaces applying WELL is to positively impact the health and well-being of more people in more places and to begin to truly change the narrative around how we design and operate the spaces where we spend our time.
“So much of WELL’s success is due to our WELL APs and WELL Faculty, an active and growing community that brings education about WELL to colleagues and clients around the world,” he continued. “Together with the market reach of our 130+ organizational members, this combined leadership has played a critical role in IWBI’s journey towards market transformation, one that puts the people we care about squarely in the center of every decision we make.”
Over the course of 2019, nearly four times as many new projects registered to pursue WELL as throughout all of 2018.
“Halfway to a billion is one thing, but what’s truly remarkable is the pace of adoption,” said Rachel Gutter, President of IWBI. “WELL entered the market in 2014, and it took roughly four years to reach 250 million square feet, but it’s only taken a year to double that to a half-billion. While that’s a potent market signal, it really reflects an unbelievable rise of a dedicated community around the world that is committed to investing in health.”
To build upon this growth and momentum, IWBI also has leveraged new partnership opportunities to reach priority markets and scale the benefits of delivering better buildings.
“We are fostering a global movement to radically transform how we deliver on the promise of better buildings that help all people thrive,” said Gutter. “We know we can’t do it alone. That’s why last year we announced a partnership with Enterprise Community Partners to bridge sustainability and health by integrating WELL with the Enterprise 2020 Green Communities Criteria, which is the leading building standard for green affordable housing construction nationwide.” Currently 27 states and Washington D.C. require or incentivize Enterprise Green Communities certification for affordable housing developments that receive public funds. Beginning in October projects meeting these requirements will also be certified to WELL.
“As we continue to scale across every dimension, it becomes more important than ever that we find a place and time for our community to experience the power of this movement,” said Fedrizzi. “That’s why in two short months, we’ll convene in Scottsdale, Arizona, for the launch of The WELL Conference , a gathering designed to inspire, energize and celebrate the people and organizations who are helping us change the world.”
In collaboration with the American Society of Interior Designers (ASID) and Emerald Expositions (Emerald), The WELL Conference will bring together architectural, design and engineering communities, along with real estate developers, corporate officials, public health practitioners, and technology companies. Centered on the idea that our buildings and communities are fundamental to our health and well-being, the event will unite a diverse representation of industries and sectors around a shared mission.
“Given these enormous accomplishments in just the five years since WELL first launched, we’re beyond excited to see what this new decade will bring,” said Fedrizzi. “Every new project, WELL AP, WELL Faculty and IWBI member helps us take more steps forward in this journey. And when the mission is to improve the health of people, every milestone is worth celebrating.”
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. WELL v2 is the latest version of its popular WELL Building Standard, and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here .
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005834/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
